Clinical manifestations of HBsAg and anti-HCV negative chronic liver disease in Nagasaki Prefecture, Japan

被引:4
|
作者
Omagari, K
Komatsu, K
Kato, Y
Nakata, K
Kusumoto, Y
Mori, I
Furukawa, R
Tanioka, H
Tajima, H
Koga, M
Yano, M
机构
[1] Second Dept. of Internal Medicine, Nagasaki University, School of Medicine, Nagasaki
[2] First Dept. of Internal Medicine, Nagasaki University, School of Medicine, Nagasaki
[3] Department of Internal Medicine, Nagasaki City Hospital, Nagasaki
[4] Department of Internal Medicine, Nagasaki Red Cross Atom. Bomb Hosp., Nagasaki
[5] Department of Internal Medicine, Sasebo Municipal General Hospital, Sasebo
[6] Department of Internal Medicine, Nagasaki Rousai Hospital, Sasebo
[7] Institute for Clinical Research, Nagasaki Chuo National Hospital, Omura
[8] Second Dept. of Internal Medicine, Nagasaki University, School of Medicine, Nagasaki 852
关键词
non-B; non-C chronic liver disease; liver cirrhosis; hepatocellular carcinoma; longterm prognosis;
D O I
10.2169/internalmedicine.35.600
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The discovery of hepatitis C virus (HCV) has enabled the diagnosis of type C chronic liver disease, which had in the past been diagnosed as part of non-A, non-B chronic liver disease, Although most cases with chronic liver disease are caused by hepatitis B virus (HBV) or HCV infection, there are still cases of non-B, non-C chronic liver disease, Forty patients with chronic liver disease, who were seronegative for hepatitis B surface antigen and antibody to HCV, were followed for a mean period of 72 months, The clinical manifestations in these patients were compared with those reported for type B and type C chronic liver disease, Of the 40 patients, 22 were diagnosed with chronic hepatitis, 14 with liver cirrhosis and 4 with hepatocellular carcinoma (HCC), Twenty-seven (67.5%) patients showed mild alanine aminotransferase activity profiles, and the natural clinical course of most patients showed a slow progression compared with that reported for type B and type C patients, The yearly incidence of HCC was 9.7% in patients with liver cirrhosis and 3.9% in chronic hepatitis, These rates were similar to those in type B or type C patients, This suggests that our population sample contained a number of patients with type B, type C or other etiologic agent(s), because 66.7% of the patients who developed HCC had some evidence of exposure to HBV or HCV, Our results suggest that more detailed and accurate tests for detecting HBV and HCV should be considered before making the diagnosis of non-B, non-C chronic liver disease, and that there is the need to reveal unknown etiologic agent(s).
引用
下载
收藏
页码:600 / 604
页数:5
相关论文
共 50 条
  • [1] Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis
    Sagnelli, E
    Pasquale, G
    Coppola, N
    Marrocco, C
    Scarano, F
    Imparato, M
    Sagnelli, C
    Scolastico, C
    Piccinino, F
    JOURNAL OF MEDICAL VIROLOGY, 2005, 75 (02) : 222 - 226
  • [2] Is alcohol a risk factor for liver cirrhosis in HBsAg and anti-HCV negative subjects?
    Corrao, G
    Arico, S
    Zambon, A
    Torchio, P
    Lepore, AR
    Busellu, G
    diOrio, F
    Morelli, D
    Moscatello, MR
    Stefanini, GF
    Chiesa, R
    Donato, F
    Tomasoni, V
    Guglielmini, V
    Manghisi, OG
    Petruzzi, J
    Monica, M
    Sardi, GF
    Ajello, A
    Freni, MA
    Spadaro, A
    Gravina, M
    Longo, G
    Magano, C
    Ascione, A
    DeLuca, M
    Lanza, AG
    Blanco, GDV
    DiMauro, M
    Loguercio, C
    Burra, P
    Mioni, D
    Naccarato, R
    Guarnone, F
    Pallavicini, C
    Vittadini, G
    Orlandi, GD
    Marchionni, F
    Rabitti, G
    Caracciolo, P
    Cincis, M
    Giovannone, M
    Attili, A
    Caione, F
    Ercole, C
    Festuccia, V
    Giandomenico, G
    Giusti, A
    Grimaldi, A
    Iannessi, A
    JOURNAL OF HEPATOLOGY, 1997, 27 (03) : 470 - 476
  • [3] Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:: influence of HBsAg and anti-HCV status
    Trevisani, F
    D'Intino, PE
    Morselli-Labate, AM
    Mazzella, G
    Accogli, E
    Caraceni, P
    Domenicali, M
    De Notariis, S
    Roda, E
    Bernardi, M
    JOURNAL OF HEPATOLOGY, 2001, 34 (04) : 570 - 575
  • [4] Prevalence of anti-HCV antibodies in chronic liver disease in the Czech Republic
    J. Stránsky
    M. Hořejšová
    A. Chlumská
    E. Honzáková
    J. Vandasová
    V. Němeček
    Infection, 1997, 25 : 49 - 50
  • [5] Prevalence of anti-HCV antibodies in chronic liver disease in the Czech Republic
    Stransky, J
    Horejsova, M
    Chlumska, A
    Honzakova, E
    Vandasova, J
    Nemecek, V
    INFECTION, 1997, 25 (01) : 49 - 50
  • [6] HCV-RNA AND LIVER-DISEASE IN CHRONIC ASYMPTOMATIC CARRIERS OF ANTI-HCV
    PONTISSO, P
    MORSICA, G
    CAVALLETTO, D
    RUVOLETTO, D
    CHEMELLO, L
    ALBERTI, A
    HEPATOLOGY, 1992, 16 (02) : 584 - 584
  • [7] Anti-HCV testing and autoimmune liver disease
    不详
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 10 (01): : 19 - 20
  • [8] IGM ANTI-HCV IN SUBJECTS WITH AND WITHOUT HCV-RELATED CHRONIC LIVER-DISEASE
    MORISCO, F
    TUCCILLO, C
    ROMANO, M
    PERSICO, M
    DESIO, I
    CAPORASO, N
    GASTROENTEROLOGY, 1994, 106 (04) : A945 - A945
  • [9] Influence of HBsAg and anti-HCV status on the diagnostic accuracy of alpha(1)-fetoprotein (AFP) in patients with chronic liver disease.
    Trevisani, F
    MorselliLabate, AM
    Calandra, S
    DeNotariis, S
    DIntino, PE
    Accogli, E
    Mazzella, PG
    Caraceni, P
    Raimondo, G
    Bernardi, M
    HEPATOLOGY, 1997, 26 (04) : 173 - 173
  • [10] THE CLINICAL OUTCOME OF HBSAG AND ANTI-HCV POSITIVE RENAL-ALLOGRAFT
    SONG, HY
    KANG, SW
    CHOI, KH
    HA, SK
    LEE, HY
    HAN, DS
    OH, CK
    KIM, YS
    PARK, K
    KIDNEY INTERNATIONAL, 1995, 47 (01) : 361 - 361